June's AI-picked stock updates now live. See what's new in Tech Titans, up 28.5% year to date.Unlock Stocks

Here's Why Investors Should Sell Patterson Companies Now

Published 10/16/2017, 06:05 AM
Updated 07/09/2023, 06:31 AM
HSIC
-
PDCO
-
LMNX
-
SONVY
-

Patterson Companies Inc. (NASDAQ:PDCO) has had a dismal run on the bourses of late. Year to date, the company has lost 8.8%, underperforming the broader industry’s gain of 15.3%.

A rapidly changing healthcare environment in the United States, unfavorable price movement, a competitive dental products distribution industry and integration risks pose significant challenges for the company.

Political Qualms: The ongoing political conundrum pertaining to the repealing of Obamacare by the Republicans has given rise to uncertainties in the dental space. Last week, the MedTech space received a heavy blow with Trump’s latest ‘Executive Order,’ where he pulled the plug on Obamacare subsidies that reduce net health care costs for Americans with low income again.

These legislations and regulations are expected to affect expenditures or reimbursements for dental services through private dental insurance plans. We believe this will mar Patterson’s overall results in the quarters to come.

Dental Segment Lacks Luster: Patterson’s dental segment contributes significantly to total revenue every year (42.7% of net revenues in fiscal 2017). However, decrease in sales of CEREC and other digital technology equipment is likely to mar revenues for dental consumables and dental equipment.

Furthermore, management at Patterson anticipates headwinds in technology equipment business to persist through fiscal 2018 as the company transitions to its new go-to market strategy with an expanded technology product portfolio.

Declining Estimates: The estimate revision trend for Patterson has been unfavorable. For the full and next year, two analysts moved south compared to no movement in the opposite direction over the last two months.

As a result, the Zacks Consensus Estimate for the full year inched down 0.9% to $2.29 per share. The next-year earnings estimates dropped 1.2% to $2.48 per share. The stock has a Zacks Rank #4 (Sell).

Cutthroat Competition: The U.S. dental products distribution industry is highly competitive and consists principally of national, regional and local full-service and mail-order distributors. Patterson faces competition from another national full-service firm, Henry Schein Dental, a unit of Henry Schein (NASDAQ:HSIC) .

In addition, there are at least 15 full-service distributors that operate on a regional level and hundreds of small local distributors. Patterson needs to continue to introduce products in the market to counter competition. Failure to do so will dent the company’s market share.

Key Picks

A few better-ranked stocks in the broader medical sector are SONOVA HOLDING (OTC:SONVY) and Luminex Corp. (NASDAQ:LMNX) . SONOVA and Luminex sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

SONOVA represented a solid return of 14.5% over the last year. The company has a long-term expected earnings growth rate of 7%.

Luminex came up with a positive earnings surprise of 188.9% last quarter. The stock has a long-term expected earnings growth rate of 16.3%.

5 Trades Could Profit "Big-League" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates and spending surges in defense and infrastructure.

See these buy recommendations now >>



Luminex Corporation (LMNX): Free Stock Analysis Report

Henry Schein, Inc. (HSIC): Free Stock Analysis Report

Patterson Companies, Inc. (PDCO): Free Stock Analysis Report

SONOVA HOLDING (SONVY): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.